Stay updated with breaking news from Laminar Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Johnson & Johnson to acquire Shockwave Medical for $335.00/share in cash, bolstering its cardiovascular intervention portfolio. The acquisition, expected to close by mid-2024, signifies Johnson & Johnson's strategic focus on innovation and market expansion.
Med-tech powerhouse Johnson & Johnson made a bold bid to bolster its interventional cardiology holdings with the news on April 5 that it is acquiring Shockwave Medical Inc. for approximately $13.1 billion including cash acquired. The $335 per share cash price represents a more than 5% premium to Shockwave’s (Nasdaq: SWAV) April 4 closing price and a more than 17% premium to the stock price prior to the Wall Street Journal report last week about the rumoured deal.
Investigational device designed for Left Atrial Appendage Elimination (LAAX) to reduce the risk of stroke in patients with non-valvular atrial fibrillation
News and analysis on legal developments including litigation filings, case settlements, verdicts, regulation, enforcement, legislation, corporate deals, and business of law.
Johnson & Johnson’s stock was slightly higher premarket Tuesday, after the healthcare company set guidance for 2024 and for the longer term, ahead of an...